Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;14(4):300-306.
doi: 10.6004/jadpro.2023.14.4.4. Epub 2023 May 1.

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin

Rebecca Lu  1 , Ashley Morphey  1 , Felicia Diaz  1 , Jessica Chen  1 , Azadeh Razmandi  1 , Tiffany Richards  1
Affiliations
Review

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin

Rebecca Lu et al. J Adv Pract Oncol. 2023 May.

Abstract

While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for more treatment modalities remains, as patients who are refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies have a median survival of only 5.8 to 13 months. Belantamab mafodotin, a first-in-class antibody-drug conjugate, was approved by the US Food and Drug Administration in 2020 for patients with relapsed or refractory myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It produced an overall response rate of 31%, and the median progression-free survival was 2.9 months when administered as a single agent. While generally well tolerated, ocular toxicities were a notable adverse event reported. In this article, we discuss the response data, toxicity profile including ocular toxicities, and treatment management.

PubMed Disclaimer

Conflict of interest statement

Ms. Lu has served as a consultant for GSK. The other authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Retro-illumination of sparse diffuse microcysts. Grade 1 treatment is artificial tears every 2 hours in both eyes. Did not decrease in best corrected vision. Used with permission from A. Razmandi, MD Anderson Cancer Center, slit-lamp photography (2021).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. American Cancer Society. (2023). Key statistics about multiple myeloma. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistic...
    1. Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J. (2015). Ocular adverse events associated with antibody-drug conjugates in human clinical trials. Journal of Ocular Pharmacology and Therapeutics, 31(10), 589–604. 10.1089/jop.2015.0064 - DOI - PMC - PubMed
    1. Farooq, A. V., Degli Esposti, S., Popat, R., Thulasi, P., Lonial, S., Nooka, A. K.,…Colby, K. (2020). Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmology and Therapy, 9(4), 889–911. 10.1007/s40123-020-00280-8 - DOI - PMC - PubMed
    1. GSK. (2020). FDA approves GSK's BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma. https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-blenre...
    1. GSK. (2022). GSK Provides Update on DREAMM-3 Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dr...

LinkOut - more resources